Oncolytics Biotech Anticipates Final Action For Its Track 1 Prioritized Examination Patent Application With U.S. PTO In Q4

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property ("IP") portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company's long-term value creation and development strategy.

In early Q3 2025, Oncolytics filed a Track 1 prioritized examination patent application with the United States Patent and Trademark Office ("USPTO") focused on manufacturing-related innovations for pelareorep. If granted, this patent application could result in granted claims with a potential term extending to 2044, significantly lengthening the commercial runway for pelareorep.

The company received initial written feedback from the USPTO in Q4 2025. Based on the Track 1 timeline, Oncolytics expects a final action in Q3 2026 regarding this manufacturing patent application.